These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 6217585)

  • 21. Fibrin-specific thrombolytic agents.
    Collen D
    Schweiz Med Wochenschr; 1987 Nov; 117(46):1791-8. PubMed ID: 3122317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence for an active fibrinolytic system in normal human bone marrow.
    McWilliam NA; Robbie LA; Barelle CJ; Adey G; Prasad S; Bennett B; Booth NA
    Br J Haematol; 1996 Apr; 93(1):170-6. PubMed ID: 8611456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inherited disorders of the fibrinolytic pathway.
    Jain S; Acharya SS
    Transfus Apher Sci; 2019 Oct; 58(5):572-577. PubMed ID: 31427261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The search for the ideal thrombolytic agent.
    Verstraete M
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):4B-10B. PubMed ID: 2959714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Laboratory control of fibrinolytic therapy].
    Vinazzer H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(1-2):30-7. PubMed ID: 2427412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The susceptibility of plasma to activation of fibrinolysis.
    Stief TW
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):123-5. PubMed ID: 8457639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of chromogenic substrate assays for fibrinolytic analytes in dogs.
    Lanevschi A; Kramer JW; Greene SA; Meyers KM
    Am J Vet Res; 1996 Aug; 57(8):1124-30. PubMed ID: 8836361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An enzyme-linked immunosorbent assay (ELISA) for the measurement of plasmin-alpha 2-antiplasmin complex in human plasma--application to the detection of in vivo activation of the fibrinolytic system.
    Holvoet P; de Boer A; Verstreken M; Collen D
    Thromb Haemost; 1986 Oct; 56(2):124-7. PubMed ID: 2433784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The behavior of alpha2-plasmin inhibitor in fibrinolytic states.
    Aoki N; Moroi M; Matsuda M; Tachiya K
    J Clin Invest; 1977 Aug; 60(2):361-9. PubMed ID: 68962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Streptokinase or urokinase: the elements of choice].
    Pâques EP
    Haemostasis; 1986; 16 Suppl 4():21-5. PubMed ID: 2429902
    [No Abstract]   [Full Text] [Related]  

  • 31. H-D-val-leu-lys-aminoisophthalic acid, dimethyl ester, is sensitive to streptokinase-activator not to plasmin.
    Ts'ao C; Galluzzo TS
    Am J Clin Pathol; 1981 Mar; 75(3):372-7. PubMed ID: 6452054
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro comparison of fibrinolytic activity of plasminogen activators using a thrombelastographic method: in vivo evaluation of the B-chain-streptokinase complex in the dog model using pre-titered doses.
    Summaria L; Sandesara J; Yang G; Vagher JP; Caprini JA
    Thromb Haemost; 1986 Aug; 56(1):71-9. PubMed ID: 2946093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Behavior of human plasmin inhibitors in intravascularly increased fibrinolytic activity].
    Fischer M
    Thromb Diath Haemorrh; 1970 Jun; 23(3):513-52. PubMed ID: 4247030
    [No Abstract]   [Full Text] [Related]  

  • 34. Fibrinolytic therapy.
    Gallus AS
    Compr Ther; 1976 Apr; 2(4):67-73. PubMed ID: 131019
    [No Abstract]   [Full Text] [Related]  

  • 35. [Effect of the enzyme preparation longolytin on fibrinolysis in animals].
    Serebriakova TN; Andreenko GV; Tsymanovich SG; Maksimova RA; Sharkova TS
    Nauchnye Doki Vyss Shkoly Biol Nauki; 1985; (2):66-71. PubMed ID: 3157406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intracellular activation of the fibrinolytic cascade in the Quebec Platelet Disorder.
    Sheth PM; Kahr WH; Haq MA; Veljkovic DK; Rivard GE; Hayward CP
    Thromb Haemost; 2003 Aug; 90(2):293-8. PubMed ID: 12888877
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasmin-alpha 2-antiplasmin complexes in bleeding disorders characterized by primary or secondary fibrinolysis.
    Booth NA; Bennett B
    Br J Haematol; 1984 Apr; 56(4):545-56. PubMed ID: 6201189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The haemostatic balance in groups of thrombosis-prone patients. With particular reference to fibrinolysis in patients with myocardial infarction.
    Gram J
    Dan Med Bull; 1990 Jun; 37(3):210-34. PubMed ID: 2192835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Do thrombolytic agents prevent postphlebitis thromboembolism?].
    Trübestein G
    Haemostasis; 1986; 16 Suppl 4():40-53. PubMed ID: 3490419
    [No Abstract]   [Full Text] [Related]  

  • 40. On the reliability of plasminogen measurement employing the proactivator-activator converting method.
    Martin M
    Thromb Haemost; 1976 Dec; 36(3):551-65. PubMed ID: 138961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.